Management of macular edema due to central retinal vein occlusion – The role of aflibercept

• Main Authors: William Rhoades, Drew Dickson, Quan Dong Nguyen, Diana V Do
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2017-01-01
• Series: Taiwan Journal of Ophthalmology
• Subjects: Aflibercept; antivascular endothelial growth factor; central retinal vein occlusion
• Online Access: http://www.e-tjo.org/article.asp?issn=2211-5056;year=2017;volume=7;issue=2;spage=70;epage=76;aulast=Rhoades
• ISSN: 2211-5056; 2211-5072

Central retinal vein occlusion (CRVO) can cause vision loss. The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab and they are effective at blocking VEGF. In addition, intraocular steroids can be used to treat macular edema. This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.